Key Takeaways The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns. The moves came as one patient who took the combination shot reported nerve damage. The company said it was working with the FDA to get the information necessary to resolve the issue and allow the company to move forward with testing. Novavax (NVAX) shares plummeted nearly 20% Wednesday after the Food and Drug Administration (FDA) stopped ...